HPV-Targeted T Cells May Be Effective for Metastatic Cervical Cancer
Regression of metastatic cervical cancer can occur after a single infusion of HPV-targeted tumor-infiltrating T cells.
Durable, complete regression of metastatic cervical cancer can occur after a single infusion of human papillomavirus (HPV)-targeted tumor-infiltrating T cells (HPV-TILs), a new study published online this week in the Journal of Clinical Oncology has shown.
For the study, researchers sought to evaluate the effect of adoptive t-cell therapy on regression of metastatic cervical cancer.
Researchers enrolled nine patients with metastatic cervical cancer who had previously received platinum-based chemotherapy or chemoradiotherapy. All patients received lymphocyte-depleting chemotherapy, followed by an administration of aldesleukin.
Then, patients received a single infusion of TILs selected when possible to target HPV E6 and E7.
Results showed that two patients achieved a complete response and one patient achieve a partial response.
Those who achieved a complete response were ongoing 22 and 15 months after treatment, respectively. The patient who achieved a partial response was 3 months in duration.
RELATED: Nomograms Predict Locally Advanced Cervical Cancer Recurrence, Patient Survival
Researchers also found that the frequency of HPV-reactive T cells in peripheral blood 1 month after treatment was positively associated with clinical response (P = 0.0238).
The authors conclude that continued investigation of this therapy is warranted.
Preliminary findings were presented at the 50th Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois.